BackPRA Health Sciences Overview
PRA Health Sciences Inc

PRA Health Sciences Return on Equity

PRA Health Sciences (PRAH) has a ROE of 13.71%, above the Healthcare sector average of 13.1%.

Get informed when a big investor buys or sells

+ Follow

ROE

13.71%

Return on Equity

13.71%

Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.

ROE (Comparison Companies)

Loading

ROE History

Loading

ROE Comparison

Loading

PRA Health Sciences (PRAH) FAQ

PRA Health Sciences posts a ROE of 13.71%. That is above the Healthcare sector average of 13.1%. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

For Healthcare stocks, a ROE near 13.1% is typical. PRA Health Sciences's 13.71% is higher that level. That is roughly 4.6% above the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.

PRA Health Sciences's ROE moves when the underlying profit, equity, or asset base changes. Cost cuts, pricing power, buybacks, write-downs, and cyclical swings can all shift the percentage. The latest reading is 13.71%; use YoY and peer views to separate noise from signal.

Context for PRAH's ROE usually means three checks: (1) trend versus prior periods, (2) level versus peers (average 13.1%), and (3) consistency with growth and profitability. This page covers the first two; PRA Health Sciences's other metric pages and overview cover the third.

Judging PRA Health Sciences against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in ROE easier to interpret. Start with 13.71% here, then scan peer and history charts to see if the gap is persistent.